Asset Details
Do you wish to reserve the book?
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
Do you wish to request the book?
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
2017
Overview
Fibroblast growth factor (FGF) 23 is a phosphaturic hormone that directly targets cardiac myocytes via FGF receptor (FGFR) 4 thereby inducing hypertrophic myocyte growth and the development of left ventricular hypertrophy (LVH) in rodents. Serum FGF23 levels are highly elevated in patients with chronic kidney disease (CKD), and it is likely that FGF23 directly contributes to the high rates of LVH and cardiac death in CKD. It is currently unknown if the cardiac effects of FGF23 are solely pathological, or if they potentially can be reversed. Here, we report that FGF23-induced cardiac hypertrophy is reversible
in vitro
and
in vivo
upon removal of the hypertrophic stimulus. Specific blockade of FGFR4 attenuates established LVH in the 5/6 nephrectomy rat model of CKD. Since CKD mimics a form of accelerated cardiovascular aging, we also studied age-related cardiac remodeling. We show that aging mice lacking FGFR4 are protected from LVH. Finally, FGF23 increases cardiac contractility via FGFR4, while known effects of FGF23 on aortic relaxation do not require FGFR4. Taken together, our data highlight a role of FGF23/FGFR4 signaling in the regulation of cardiac remodeling and function, and indicate that pharmacological interference with cardiac FGF23/FGFR4 signaling might protect from CKD- and age-related LVH.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/95
/ 14/19
/ 38/77
/ 64/110
/ 82/29
/ 82/51
/ 82/80
/ 96/95
/ Aging
/ Animals
/ Aorta
/ Biopsy
/ Diet
/ Fibroblast growth factor receptor 4
/ Fibroblast growth factor receptors
/ Fibroblast Growth Factors - blood
/ Fibroblast Growth Factors - metabolism
/ Heart
/ Humanities and Social Sciences
/ Hypertrophy, Left Ventricular - etiology
/ Hypertrophy, Left Ventricular - metabolism
/ Hypertrophy, Left Ventricular - pathology
/ Mice
/ Myocardial Contraction - genetics
/ Myocytes
/ Myocytes, Cardiac - metabolism
/ Rats
/ Receptor, Fibroblast Growth Factor, Type 4 - antagonists & inhibitors
/ Receptor, Fibroblast Growth Factor, Type 4 - metabolism
/ Rodents
/ Science
